# A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to Moderate Hypertension

> **NCT00133185** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 31 (—)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** telmisartan 40 mg/hydrochlorothiazide 12.5 mg
- **DRUG:** losartan 50 mg/hydrochlorothiazide 12.5 mg

## Key facts

- **NCT ID:** NCT00133185
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2005-03
- **Final completion:** 2005-03
- **Target enrollment:** 31 (—)
- **Last updated:** 2013-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00133185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00133185, "A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to Moderate Hypertension". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00133185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*